Segment, Geographic and Other Revenue Information - Revenues By Products (Detail) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 30, 2018	Oct. 01, 2017	Sep. 30, 2018	Oct. 01, 2017
Revenue from External Customer [Line Items]
Revenues	[1]	$ 13,298	$ 13,168	$ 39,670	$ 38,843
Innovative Health and Essential Health [Member]
Revenue from External Customer [Line Items]
Revenues		13,298	13,168	39,670	38,843
Innovative Health and Essential Health [Member] | Lyrica [Member]
Revenue from External Customer [Line Items]
Revenues	[2]	1,213	1,285	3,649	3,810
Innovative Health and Essential Health [Member] | Viagra [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	137	308	509	996
Innovative Health and Essential Health [Member] | Alliance revenues [Member]
Revenue from External Customer [Line Items]
Revenues		977	741	2,820	2,112
Innovative Health Business [Member] | IH [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	8,471	8,118	24,573	23,204
Essential Health Business [Member] | EH [Member]
Revenue from External Customer [Line Items]
Revenues	[5]	4,826	5,050	15,097	15,639
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member]
Revenue from External Customer [Line Items]
Revenues	[6]	2,533	2,681	7,865	7,995
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Lipitor [Member]
Revenue from External Customer [Line Items]
Revenues		507	491	1,539	1,341
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Norvasc [Member]
Revenue from External Customer [Line Items]
Revenues		247	226	773	684
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Premarin family [Member]
Revenue from External Customer [Line Items]
Revenues		204	238	605	711
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Xalatan/Xalacom [Member]
Revenue from External Customer [Line Items]
Revenues		76	83	233	241
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Effexor [Member]
Revenue from External Customer [Line Items]
Revenues		78	76	228	215
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Zoloft [Member]
Revenue from External Customer [Line Items]
Revenues		72	78	223	215
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Zithromax [Member]
Revenue from External Customer [Line Items]
Revenues		54	61	216	202
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | EpiPen [Member]
Revenue from External Customer [Line Items]
Revenues		68	82	215	253
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Xanax [Member]
Revenue from External Customer [Line Items]
Revenues		52	58	163	164
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Sildenafil Citrate [Member]
Revenue from External Customer [Line Items]
Revenues		1	0	72	0
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Other Legacy Established Products [Member]
Revenue from External Customer [Line Items]
Revenues		1,176	1,288	3,599	3,969
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member]
Revenue from External Customer [Line Items]
Revenues	[7]	1,239	1,273	3,928	4,270
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | Sulperazon [Member]
Revenue from External Customer [Line Items]
Revenues		145	114	464	345
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | Medrol [Member]
Revenue from External Customer [Line Items]
Revenues		95	109	318	352
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | Fragmin [Member]
Revenue from External Customer [Line Items]
Revenues		76	79	221	221
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | Tygacil [Member]
Revenue from External Customer [Line Items]
Revenues		60	60	186	192
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | Tazosyn / Zosyn [Member]
Revenue from External Customer [Line Items]
Revenues		55	47	175	124
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | Precedex [Member]
Revenue from External Customer [Line Items]
Revenues		47	51	166	182
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | All Other Sterile Injectable Pharmaceuticals [Member]
Revenue from External Customer [Line Items]
Revenues		761	814	2,399	2,852
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member]
Revenue from External Customer [Line Items]
Revenues	[8]	698	794	2,208	2,398
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Lyrica [Member]
Revenue from External Customer [Line Items]
Revenues	[2]	81	134	251	428
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Viagra [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	137	102	509	285
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Celebrex [Member]
Revenue from External Customer [Line Items]
Revenues		188	212	494	564
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Vfend [Member]
Revenue from External Customer [Line Items]
Revenues		87	97	294	305
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Zyvox [Member]
Revenue from External Customer [Line Items]
Revenues		50	68	184	220
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Revatio [Member]
Revenue from External Customer [Line Items]
Revenues		53	58	163	189
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Pristiq [Member]
Revenue from External Customer [Line Items]
Revenues		52	69	156	230
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | All Other Peri-LOE Products [Member]
Revenue from External Customer [Line Items]
Revenues		49	55	157	176
Biosimilars [Member] | Essential Health Business [Member] | EH [Member]
Revenue from External Customer [Line Items]
Revenues	[9]	197	141	558	367
Biosimilars [Member] | Essential Health Business [Member] | EH [Member] | Inflectra/Remsima [Member]
Revenue from External Customer [Line Items]
Revenues		166	112	469	284
Biosimilars [Member] | Essential Health Business [Member] | EH [Member] | All Other Biosimilars [Member]
Revenue from External Customer [Line Items]
Revenues		31	28	89	82
CentreOne [Member] | Essential Health Business [Member] | EH [Member]
Revenue from External Customer [Line Items]
Revenues	[10]	159	161	539	514
Hospira Infusion Systems (HIS) [Member] | Essential Health Business [Member] | EH [Member]
Revenue from External Customer [Line Items]
Revenues	[11]	0	0	0	97
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member]
Revenue from External Customer [Line Items]
Revenues		2,463	2,455	7,339	7,245
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | Lyrica [Member]
Revenue from External Customer [Line Items]
Revenues	[2]	1,132	1,150	3,398	3,382
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | Eliquis [Member]
Revenue from External Customer [Line Items]
Revenues		870	644	2,524	1,813
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | Chantix / Champix [Member]
Revenue from External Customer [Line Items]
Revenues		261	240	789	727
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | B M P 2 [Member]
Revenue from External Customer [Line Items]
Revenues		54	79	206	198
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | Toviaz [Member]
Revenue from External Customer [Line Items]
Revenues		67	62	197	187
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | Viagra [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	0	206	0	711
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | All Other Internal Medicine [Member]
Revenue from External Customer [Line Items]
Revenues		79	75	224	228
Vaccines [Member] | Innovative Health Business [Member] | IH [Member]
Revenue from External Customer [Line Items]
Revenues		1,845	1,649	4,708	4,385
Vaccines [Member] | Innovative Health Business [Member] | IH [Member] | Prevnar 13/Prevenar 13 [Member]
Revenue from External Customer [Line Items]
Revenues		1,660	1,522	4,290	4,069
Vaccines [Member] | Innovative Health Business [Member] | IH [Member] | FSME-IMMUN/TicoVac [Member]
Revenue from External Customer [Line Items]
Revenues		57	43	162	119
Vaccines [Member] | Innovative Health Business [Member] | IH [Member] | Trumenba [Member]
Revenue from External Customer [Line Items]
Revenues		61	42	95	79
Vaccines [Member] | Innovative Health Business [Member] | IH [Member] | All other Vaccines [Member]
Revenue from External Customer [Line Items]
Revenues		67	43	160	117
Oncology [Member] | Innovative Health Business [Member] | IH [Member]
Revenue from External Customer [Line Items]
Revenues		1,775	1,616	5,294	4,551
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Ibrance [Member]
Revenue from External Customer [Line Items]
Revenues		1,025	878	2,985	2,410
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Sutent [Member]
Revenue from External Customer [Line Items]
Revenues		248	276	785	805
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Xtandi Alliance [Member]
Revenue from External Customer [Line Items]
Revenues		180	150	510	422
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Xalkori [Member]
Revenue from External Customer [Line Items]
Revenues		127	146	417	442
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Inlyta [Member]
Revenue from External Customer [Line Items]
Revenues		71	84	226	256
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Bosulif [Member]
Revenue from External Customer [Line Items]
Revenues		69	57	206	163
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | All other Oncology [Member]
Revenue from External Customer [Line Items]
Revenues		55	26	164	54
Inflammation and Immunology (I&I) [Member] | Innovative Health Business [Member] | IH [Member]
Revenue from External Customer [Line Items]
Revenues		1,018	1,000	2,951	2,863
Inflammation and Immunology (I&I) [Member] | Innovative Health Business [Member] | IH [Member] | Enbrel (Outside the U.S. and Canada) [Member]
Revenue from External Customer [Line Items]
Revenues		531	613	1,589	1,818
Inflammation and Immunology (I&I) [Member] | Innovative Health Business [Member] | IH [Member] | Xeljanz [Member]
Revenue from External Customer [Line Items]
Revenues		432	348	1,221	935
Inflammation and Immunology (I&I) [Member] | Innovative Health Business [Member] | IH [Member] | Eucrisa [Member]
Revenue from External Customer [Line Items]
Revenues		40	15	104	33
Inflammation and Immunology (I&I) [Member] | Innovative Health Business [Member] | IH [Member] | All Other Inflammation and Immunology Products [Member]
Revenue from External Customer [Line Items]
Revenues		15	23	37	78
Rare Disease [Member] | Innovative Health Business [Member] | IH [Member]
Revenue from External Customer [Line Items]
Revenues		531	569	1,651	1,637
Rare Disease [Member] | Innovative Health Business [Member] | IH [Member] | BeneFIX [Member]
Revenue from External Customer [Line Items]
Revenues		132	151	420	453
Rare Disease [Member] | Innovative Health Business [Member] | IH [Member] | Genotropin [Member]
Revenue from External Customer [Line Items]
Revenues		143	136	416	375
Rare Disease [Member] | Innovative Health Business [Member] | IH [Member] | ReFacto AF/ Xyntha [Member]
Revenue from External Customer [Line Items]
Revenues		117	140	388	409
Rare Disease [Member] | Innovative Health Business [Member] | IH [Member] | Somavert [Member]
Revenue from External Customer [Line Items]
Revenues		64	65	195	182
Rare Disease [Member] | Innovative Health Business [Member] | IH [Member] | All Other Rare Disease [Member]
Revenue from External Customer [Line Items]
Revenues		74	77	232	218
Consumer Healthcare [Member] | Innovative Health Business [Member] | IH [Member]
Revenue from External Customer [Line Items]
Revenues		$ 839	$ 829	$ 2,631	$ 2,522

[1] Amounts may not add due to rounding.

[2] Lyrica revenues from all of Europe, Russia, Turkey, Israel and Central Asia countries are included in Lyrica EH. All other Lyrica revenues are included in Lyrica IH. Total Lyrica revenues represent the aggregate of worldwide revenues from Lyrica IH and Lyrica EH.

[3] Viagra lost exclusivity in the U.S. in December 2017. Beginning in 2018, revenues for Viagra in the U.S. and Canada, which were reported in IH through 2017, are reported in EH (which reported all other Viagra revenues excluding the U.S. and Canada through 2017). Therefore, beginning in 2018, total Viagra revenues are reported in EH. Total Viagra revenues in 2017 represent the aggregate of worldwide revenues from Viagra IH and Viagra EH.

[4] The IH business encompasses Internal Medicine, Vaccines, Oncology, Inflammation & Immunology, Rare Disease and Consumer Healthcare.

[5] The EH business encompasses Legacy Established Products, Sterile Injectable Pharmaceuticals, Peri-LOE Products, Biosimilars, Pfizer CentreOne and HIS (through February 2, 2017).

[6] Legacy Established Products primarily include products that have lost patent protection (excluding Sterile Injectable Pharmaceuticals and Peri-LOE Products). In the fourth quarter of 2017, we sold our equity share in Hisun Pfizer. As a result, effective in the first quarter of 2018, Hisun Pfizer-related revenues, previously reported in emerging markets within All Other LEP and All Other SIP, are reported in emerging markets within Pfizer CentreOne.

[7] Sterile Injectable Pharmaceuticals includes branded and generic injectables (excluding Peri-LOE Products). In the fourth quarter of 2017, we sold our equity share in Hisun Pfizer. As a result, effective in the first quarter of 2018, Hisun Pfizer-related revenues, previously reported in emerging markets within All Other LEP and All Other SIP, are reported in emerging markets within Pfizer CentreOne.

[8] Peri-LOE Products includes products that have recently lost or are anticipated to soon lose patent protection. These products primarily include: Lyrica in Europe, Russia, Turkey, Israel and Central Asia; worldwide revenues for Celebrex, Pristiq, Zyvox, Vfend, Revatio and Inspra; and beginning in 2018, Viagra revenues for all countries (and Viagra revenues for all countries other than the U.S. and Canada in 2017, see note (c) above).

[9] Biosimilars includes Inflectra/Remsima (biosimilar infliximab) in the U.S. and certain international markets, Nivestim (biosimilar filgrastim) in certain European, Asian and Africa/Middle Eastern markets and in the U.S. and Retacrit (biosimilar epoetin zeta) in certain European and Africa/Middle Eastern markets.

[10] Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements, including with Zoetis Inc. In the fourth quarter of 2017, we sold our equity share in Hisun Pfizer. As a result, effective in the first quarter of 2018, Hisun Pfizer-related revenues, previously reported in emerging markets within All Other LEP and All Other SIP, are reported in emerging markets within Pfizer CentreOne.

[11] HIS (through February 2, 2017) includes Medication Management Systems products composed of infusion pumps and related software and services, as well as IV Infusion Products, including large volume IV solutions and their associated administration sets.